Genome editing tools enable precise changes to the genome of an organism. Applied worldwide by researchers in academia, public institutions, and industry, these innovations represent a promising next step towards beneficial uses in medicine, agriculture and the bio-economy aimed at addressing some of society’s grand challenges. Check out our ‘What if’ series that explores precisely how genome editing can help tackle these challenges. In the EU, many of these beneficial uses are unlikely to find a path to the market, unless the current regulatory framework is modernised. This section offers you more information on genome editing and the EU policy debate.
Over 20 EU business associations call for innovation-friendly rules on mutagenesis
An open letter jointly calls upon member states and the EU Commission to initiate a legislative change to ensure that targeted genetic variation in organisms can help Europe to achieve important sustainable development goals.
Court ruling could lock out the benefits of genome editing from Europe
Responding to today’s Court of Justice of the EU ruling on organisms obtained by mutagenesis (Case C-528/16), EuropaBio’s Secretary General John Brennan highlighted industry’s concerns about the judgement.